Search

Displaying results 1521 - 1530 of 4262 in total
  1. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

  2. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. … Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels.

  3. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    by a reduced number of mature neutrophils and lymphocytes. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.

  4. Drug

    Parathyroid hormone

    go.drugbank.com/drugs/DB05829
    ApprovedInvestigational

    Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA). … Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed.

  5. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.

  6. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    It is an investigational drug under regulatory review by FDA. … Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.

  7. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    Allergens containing disulfide bonds are inactivated when reduced by thioredoxin. … It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site.

  8. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.

  9. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    monosaccharides which can be absorbed by the body. … Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.

  10. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.